Document Type : Original Article


1 Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Internal Medicine Shiraz, University of Medical Science, Shiraz, Iran.

3 Department of Pathology, University of Medical Science, Shiraz, Iran

4 Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran



Systemic sclerosis (SSc) is a systemic connective tissue disease with vasculopathy and tissue fibrosis. Mean platelet volume (MPV) indicates the platelet activation and independent risk factor for arterial diseases. Long pentraxin, or pentraxin-3 (PTX3), is a homologous pattern recognition receptor mainly presented in inflammatory diseases with some inhibitory effects on chronic inflammation. This study aimed to evaluate the relationship between clinical and capillaroscopy manifestations of patients with SSc, MPV, and PTX3 levels compared to the control group. This case-control study was conducted on patients who met the SSc diagnostic criteria. Accordingly, clinical manifestations and capillaroscopy data were recorded. Thus, the MPV and PTX3 levels of the patients and the control group were checked. Then, the relationship between the clinical and capillaroscopy results was evaluated. The mean ± SD of MPV in the control group and patients was 10.11 ± 0.96 fL and 9.65 ± 1.13 fL, respectively (Pvalue = 0.043). In addition, the PTX3 level was 3.60 ± 8.98 and 1.79 ± 5.77 ng/ml, respectively (P-value = 0.223). The relationship of these factors with the clinical and capillaroscopy results was insignificant (P-value > 0.05). Based on the results, the MPV level was significantly lower in patients with SSc than controls, while the PTX3 level did not differ between the groups. Moreover, there was no relationship between PTX3 and MPV levels with the capillaroscopy and clinical results. However, further studies with larger sample sizes are recommended.


Main Subjects

  1. References:


    1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 53(3):306-36. doi: 10.1007/s12016-017-8625-4.
    2. Li SC. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. Pediatr Clin North Am 2018; 65(4):757-81. doi: 10.1016/j.pcl.2018.04.002.


    1. Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 2012; 26(1):13-24. doi: 10.1016/j.berh.2012.01.011.


    1. Rossi D, Russo A, Manna E, Binello G, Baldovino S, Sciascia S. et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013; 12(8):821-25. doi: 10.1016/j.autrev.2012.11.006.
    2. Berger JS, Eraso LH, Xie D, Sha D, Mohler ER, 3rd. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 2010; 213(2):586-91. doi: 10.1016/j.atherosclerosis.2010.09.010.
    3. Schmoeller D, Picarelli MM, Paz Munhoz T, Poli de Figueiredo CE, Staub HL. Mean Platelet Volume and Immature Platelet Fraction in Autoimmune Disorders. Front Med (Lausanne) 2017; 4:146. doi: 10.3389/fmed.2017.00146.
    4. Bahali AG, Su O, Emiroglu N, Cengiz FP, Kaya MO, Onsun N. Evaluation of mean platelet volume in localized scleroderma. An Bras Dermatol 2017; 92(5):635-37. doi: 10.1590/abd1806-4841.20176045.
    5. Yayla ME, İlgen U, Okatan İ E, UsluYurteri E, Torgutalp M, Keleşoğlu Dinçer AB. et al. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 2020; 39(1):77-83. doi: 10.1007/s10067-019-04685-0.
    6. Soydinc S, Turkbeyler IH, Pehlivan Y, Soylu G, Goktepe MF, Bilici M. et al. Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis. Inflammation 2014; 37(1):100-6. doi: 10.1007/s10753-013-9716-x.
    7. Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D. et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol 2019; 10:823. doi: 10.3389/fimmu.2019.00823.
    8. Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan HF. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev 2020; 19(12):102584. doi: 10.1016/j.autrev.2020.102584.
    9. İlgen U, Yayla ME, Düzgün N. Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis. Clin Rheumatol 2017; 36(2):367-72. doi: 10.1007/s10067-016-3483-37.
    10. Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B. et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther 2014; 16(6):479. doi: 10.1186/s13075-014-0479-z.
    11. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-González S. et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012; 64(3):854-65. doi: 10.1002/art.33411.
    12. van Rossum AP, Pas HH, Fazzini F, Huitema MG, Limburg PC, Jonkman MF. et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006; 54(3):986-91. doi: 10.1002/art.21669.
    13. Adrovic A, Sahin S, Barut K, Durmus S, Uzun H, Kasapcopur O. Significance of pentraxin-3 in patients with juvenile scleroderma. Clin Exp Rheumatol 2017; 35 Suppl 106(4):221-22..
    14. Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E. et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol 2009; 36(5):976-83. doi: 10.3899/jrheum.080343.
    15. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T. et al. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol 2015; 67(2):498-507. doi: 10.1002/art.38953.
    16. Huang XL, Zhang L, Duan Y, Wang YJ, Wang J. Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Arch Med Res 2016; 47(3):223-31. doi: 10.1016/j.arcmed.2016.05.006.
    17. Sahin S, Adrovic A, Barut K, Durmus S, Gelisgen R, Uzun H. et al. Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus. Lupus 2017; 26(10):1089-94. doi: 10.1177/0961203317699286.
    18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr.. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15(2):202-205.
    19. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P. et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20(11):1892-96.
    20. Ingegnoli F, Herrick AL, Schioppo T, Bartoli F, Ughi N, Pauling JD. et al. Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology (Oxford) 2021; 60(3):1410-18. doi: 10.1093/rheumatology/keaa457.
    21. Smith V, Herrick AL, Ingegnoli F, Damjanov N, De Angelis R, Denton CP. et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmun Rev 2020; 19(3):102458. doi: 10.1016/j.autrev.2020.102458.
    22. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S. et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets 2010; 21(2):126-31. doi: 10.3109/09537100903470306.